期刊
CANCERS
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cancers11030272
关键词
glioblastoma; radiotherapy; CXCL12
类别
资金
- German Research Council [RTG2099]
- DKFZ-MOST Cooperation in Cancer Research [CA181]
Radiotherapy is a mainstay in glioblastoma therapy as it not only directly targets tumor cells but also depletes the tumor microvasculature. The resulting intra-tumoral hypoxia initiates a chain of events that ultimately leads to re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key component of this cascade is overexpression of the CXC-motive chemokine ligand 12 (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells and give an overview on future and current drugs that target this axis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据